Printer Friendly

SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG

    SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
    TOKYO, Nov. 21 /PRNewswire/ -- Secom Co., Ltd. (Capital 35.9 billion yen, President Kenichi Komine) through its subsidiary Tecno-Bio Co., Ltd. (Capital 24 million yen, President Takashi Nakamura) concluded a joint R and D agreement to develop a new anti-cancer drug with Harrier Inc. (Capital 756,000 dollars, President Jurg Kehrli), a Swiss American venture listed on NASDAQ and the Boston Stock Exchange.
    Tecno-Bio Co., Ltd., from its establishment in 1988, has been engaged in developing "diesel cleaner" (50 percent NOX reduction device by water-fuel emulsion), water purification apparatus and CO2 absorption system.  It is the policy of Secom that all revenue from this project shall be invested for further R and D and that for the time being Secom shall not have any contribution to its business result.
    This project is aimed at synthesizing and commercializing glycoside of a substance which is expected to have anti-cancer effect, "Tumosterone" a reproduction of a naturally-occurring substance in the thymus gland of the body that is believed to inhibit the growth of cancerous tumors through the body's immune system.  This radical new type of anti-cancer drug, "Tumosterone" which is expected to have fewer side effects because of its natural origins, had been under development by Dr. Klemke since 1988.
    Biological testing has begun at the Cancer Therapy and Research Center Institute of Drug Development in San Antonio, Texas, to confirm prior research on the product.  It is currently being tested against mammary tumor and melanoma cells, both highly virulent forms of cancer in humans.
    Since the method by which this glycoside is produced has broad applicability to other drugs, Harrier has entered into an agreement with the University of Michigan, Department of Chemistry, to verify its theoretical mechanism.
    Tumosterone was invested by Dr. Klemke of Germany, and its production method (Klemke Method) is called "glycosylation."  This is a chemical reaction by which a carbohydrate is attached to an organic molecule and is an area of intensive interest among practicing organic and medical chemists.
    The Klemke Method, compared to current technology, is a process by which such a reaction is produced more mildly, effectively and at a lower cost than presently available glycosylation methods.  It is expected to be widely applicable to drugs currently on the market as well as to drugs still under development.
    Secom, as a financially strong stockholder holding 13.9 percent of Harrier's shares, will support this joint R and D project through its Tecno-Bio subsidiary with the objective of developing with Harrier this unique drug and production method of glycoside.  The first phase of verification tests are scheduled to be completed at the University of Michigan before the end of the current year, after which efforts will be actively undertaken to license this technology.
    -0-              11/21/91 R
    /CONTACT:  Hitoshi Morimoto of Secom Co., Ltd., in Japan, 03-3348-5215/ CO:  Secom Co., Ltd.; Harrier Inc.; Tecno-Bio Co., Ltd. ST: IN:  MTC SU:  JVN PS -- NY121 -- 6209 11/21/91 22:56 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 21, 1991
Words:507
Previous Article:DIALOGBANK USSR JOINS VISA
Next Article:SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
Topics:


Related Articles
HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN; ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY
SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
HARRIER FINALIZES DRUG DEVELOPMENT AGREEMENT WITH AMERICAN DIAGNOSTICA
HARRIER TO RECEIVE PATENT ON ITS GLYCOSYLATION PROCESS
XENOVA AWARDED GRANT IN SUPPORT OF CANCER DRUG CLINICAL DEVELOPMENT PROGRAM
NeoTherapeutics' Subsidiary, NeoOncoRx, to Acquire Phase 2 Anti-Cancer Drug EO9 From NDDO Research Foundation.
NeoTherapeutics' NeoOncoRx Completes Transfer of IND for Satraplatin; Phase 3 clinical trial in prostate cancer to begin after discussions with the...
GPC Biotech presents data on 1D09C3 anticancer monoclonal antibody.
HEALTH MATTERS: Hope as shelved drugs revived.
Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters